Summary
Analyzes FDA safety databases, REMS precedents, and post-marketing safety data to identify and contextualize potential oncology safety signals.
Detailed Description
The Oncology Safety Signal Pack provides proactive safety intelligence for oncology drug development programs. It mines FDA safety databases, REMS catalog data, and published post-marketing safety reports to help sponsors anticipate, contextualize, and manage safety signals associated with their drug class and mechanism of action.
The pack identifies class-level safety signals from approved drugs in the same mechanism or target family, benchmarks adverse event incidence rates from registration trials, and maps REMS requirements imposed on analogous products. It provides early warning intelligence that can inform safety monitoring plans and risk management strategies.
Deliverables include a class-level safety signal report, an adverse event benchmarking analysis, and a REMS landscape assessment with recommendations for proactive risk management planning.
Evidence Sources
| Source | Type | Description | Refresh |
|---|---|---|---|
| FDA Adverse Event Reporting System (FAERS) | SAFETY | FDA post-marketing adverse event reports for oncology drugs searchable by drug class and event type | Quarterly |
| REMS Catalog | REGULATORY | Complete catalog of FDA-mandated REMS programs for oncology products with requirements and modifications | Monthly |
| Post-Marketing Safety Literature | LITERATURE | Published post-marketing safety analyses, signal detection studies, and pharmacovigilance reports | Weekly |
Regulatory Mapping
Risk Evaluation and Mitigation Strategies: Modifications and Revisions
Pharmacovigilance Planning
Premarketing Risk Assessment
Agent Transparency
When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.
Evidence Retriever
brew-retriever-v3
Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.
Domain Analyzer
brew-domain-analyst-v2
Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.
Evidence Synthesizer
brew-synthesizer-v2
Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.
Output Validator
brew-validator-v1
Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.
Sample Outputs
Class-Level Safety Signal Report
PDFComprehensive analysis of safety signals identified for the drug class and mechanism of action
Adverse Event Benchmarking
XLSXComparative adverse event incidence rates from registration trials of analogous oncology products
REMS Landscape Assessment
PDFAssessment of REMS requirements imposed on analogous products with risk management recommendations
Deliverables included
- Class-level safety signal intelligence report
- Adverse event incidence benchmarking table
- REMS landscape assessment with recommendations
- Safety monitoring plan recommendations
- Pharmacovigilance planning framework
Related Disease & Biomarker Mappings
| Therapeutic Area | Disease Family | Key Biomarkers | Relevance |
|---|---|---|---|
| Solid Tumors | Non-Small Cell Lung Cancer | EGFRALKPD-L1KRAS G12C | Primary |
| Solid Tumors | Breast Cancer | HER2ER/PRBRCA1/2PIK3CA | Primary |
| Hematologic Malignancies | Acute Myeloid Leukemia | FLT3-ITDIDH1/2NPM1 | Secondary |
| Solid Tumors | Colorectal Cancer | KRAS/NRASBRAF V600EMSI-H/dMMR | Secondary |
Related Packs in Oncology
Oncology Trial Design Pack
Design smarter trials with real-world precedent data
Dose Optimization Pack (Project Optimus)
Navigate the new dose optimization paradigm with confidence
Biomarker-Driven Trial Design Pack
Turn molecular insights into registration-ready trial designs
Immuno-Oncology Combination Pack
Build the regulatory case for your IO combination
Version History
Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.
Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.
Initial draft — core evidence retrieval pipeline and output schema established.
Need a Custom Evidence Pack?
Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.
Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.